Telix Pharmaceuticals Stock Price To Earnings To Growth
| TLX Stock | 24.74 0.93 3.62% |
Telix Pharmaceuticals fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Stock. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals stock.
Telix | Price To Earnings To Growth |
Telix Pharmaceuticals Company Price To Earnings To Growth Analysis
Telix Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Telix Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Telix Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 8.18 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Insiders | 41.42 % | ||||
| Shares Owned By Institutions | 17.88 % | ||||
| Price To Book | 20.50 X | ||||
| Price To Sales | 12.83 X | ||||
| Revenue | 496.66 M | ||||
| Gross Profit | 98.54 M | ||||
| EBITDA | 22.97 M | ||||
| Net Income | 5.21 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | 23.88 M | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 25.62 | ||||
| Beta | 2.38 | ||||
| Market Capitalization | 8.28 B | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
| Working Capital | 67.44 M | ||||
| Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.